ADAPTIVE BIOTECHNOLOGIES (ADPT)
US00650F1093 - Common Stock
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of...
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
Adaptive Biotechnologies announces over 65 abstracts featuring clonoSEQ MRD testing at the upcoming 66th ASH Annual Meeting...
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established...
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies...
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage...
3 Precision Medicine Stocks Tailoring Treatments
With technological developments pushing the boundaries of healthcare, these are the precision medicine stocks to consider.
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood...
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
Mighty Mites: 3 Small-Cap Stocks Packing a Powerful Punch
While small-cap stocks to buy present a higher-risk profile, these ideas may also pack considerable punch for their size.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite falling stocks.
Why Adaptive Biotechnologies Topped the Market Today
A double beat on earnings, plus positive adjustments to certain guidance items, lifted the company's shares.
ADPT Stock Earnings: Adaptive Biotechnologies Beats EPS, Beats Revenue for Q1 2024
ADPT stock results show that Adaptive Biotechnologies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage...